Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Insights - The company reported a revenue of 1.077 billion yuan for 2024, representing a year-over-year increase of 46.21%. The net profit attributable to shareholders was 128 million yuan, up 8.67% year-over-year [4]. - In Q1 2025, the company achieved a revenue of 285 million yuan, marking a 55.39% year-over-year growth, and a net profit of 26 million yuan, indicating a turnaround from losses [4]. - The company is increasing its investment in high-end production capacity and has completed significant capital expenditures, totaling 1.483 billion yuan in 2024, to enhance its competitive position in the market [6]. Financial Data and Profit Forecast - The company’s total revenue is projected to grow from 1.401 billion yuan in 2025 to 2.306 billion yuan by 2027, with year-over-year growth rates of 30.1%, 29.1%, and 27.6% respectively [5]. - The net profit attributable to shareholders is expected to rise from 187 million yuan in 2025 to 386 million yuan in 2027, with corresponding year-over-year growth rates of 46.0%, 43.0%, and 44.1% [5]. - The earnings per share are forecasted to increase from 1.64 yuan in 2025 to 3.39 yuan in 2027 [5]. Revenue and Profitability Analysis - The company’s revenue from CP testing reached 615 million yuan in 2024, a 38.91% increase year-over-year, while FT testing revenue was 367 million yuan, up 50.07% year-over-year [6]. - The gross margin for CP testing was 42.45%, and for FT testing, it was 29.16%, with slight decreases compared to the previous year [6]. - The company’s R&D investment increased by 37.16% year-over-year to 142 million yuan, reflecting a commitment to innovation and development [6].